Insider-Trading
Aktuelle Insider-Transaktionen (SEC Form 4) — Käufe und Verkäufe von Vorständen, Direktoren und Großaktionären.
| Ticker | Insider | Funktion | Datum | Transaktion | Kurs ($) | Stück | Wert ($) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| ROIV | Venker Eric | President & Immunovant CEO | 28.10.2026 | Verkauf | 36,59 | 200.000 | 7.318.000 | Form 4 |
| ROIV | Epperly Melissa B, | Director | 23.10.2026 | Steuer-Abgabe | 36,49 | 116 | 4.233 | Form 4 |
| ROIV | Epperly Melissa B, | Director | 23.10.2026 | Zuteilung | — | 513 | — | Form 4 |
| ROIV | Oren Ilan | Director | 23.10.2026 | Zuteilung | — | 810 | — | Form 4 |
| ROIV | Momtazee James C | Director | 23.10.2026 | Steuer-Abgabe | 36,49 | 77 | 2.810 | Form 4 |
| ROIV | Momtazee James C | Director | 23.10.2026 | Zuteilung | — | 383 | — | Form 4 |
| ROIV | Venker Eric | President & Immunovant CEO | 20.10.2026 | Verkauf | 35,42 | 14.144 | 500.980 | Form 4 |
| ROIV | Venker Eric | President & Immunovant CEO | 20.10.2026 | Verkauf | 35,09 | 185.856 | 6.521.687 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 16.10.2026 | Steuer-Abgabe | 33,53 | 19.976 | 669.795 | Form 4 |
| ROIV | Gline Matthew | CEO | 16.10.2026 | Steuer-Abgabe | 33,53 | 34.638 | 1.161.412 | Form 4 |
| ROIV | Epperly Melissa B, | Director | 01.10.2026 | Verkauf | 36,57 | 900 | 32.913 | Form 4 |
| ROIV | Epperly Melissa B, | Director | 01.10.2026 | Verkauf | 36,08 | 16.850 | 607.948 | Form 4 |
| ROIV | Epperly Melissa B, | Director | 01.10.2026 | Optionsausübung | 4,46 | 17.750 | 79.165 | Form 4 |
| ROIV | Roivant Sciences Ltd. | Director | 01.10.2026 | Abgabe | 5,00 | 8.967.383 | 44.836.915 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 30.09.2026 | Steuer-Abgabe | 36,57 | 46.879 | 1.714.365 | Form 4 |
| ROIV | Venker Eric | President & Immunovant CEO | 30.09.2026 | Verkauf | 36,62 | 200.000 | 7.324.000 | Form 4 |
| ROIV | Venker Eric | President & Immunovant CEO | 30.09.2026 | Optionsausübung | 3,85 | 200.000 | 770.000 | Form 4 |
| ROIV | Gline Matthew | CEO | 30.09.2026 | Steuer-Abgabe | 36,57 | 76.171 | 2.785.573 | Form 4 |
| ROIV | Torti Frank | President and Vant Chair | 30.09.2026 | Steuer-Abgabe | 36,57 | 40.309 | 1.474.100 | Form 4 |
| ROIV | Pulik Richard | CFO | 20.09.2026 | Steuer-Abgabe | 39,77 | 2.129 | 84.670 | Form 4 |
| ROIV | Humes Jennifer | Chief Accounting Officer | 20.09.2026 | Steuer-Abgabe | 39,77 | 3.880 | 154.308 | Form 4 |
| ROIV | Epperly Melissa B, | Director | 16.09.2026 | Zuteilung | — | 5.054 | — | Form 4 |
| ROIV | Gold Daniel Allen | Director | 16.09.2026 | Zuteilung | — | 5.054 | — | Form 4 |
| ROIV | Oren Ilan | Director | 16.09.2026 | Zuteilung | — | 5.054 | — | Form 4 |
| ROIV | Fitzgerald Meghan | Director | 16.09.2026 | Zuteilung | — | 5.054 | — | Form 4 |
| ROIV | Momtazee James C | Director | 16.09.2026 | Zuteilung | — | 5.054 | — | Form 4 |
| ROIV | Manchester Keith S | Director | 16.09.2026 | Zuteilung | — | 5.054 | — | Form 4 |
| ROIV | Epperly Melissa B, | Director | 15.09.2026 | Verkauf | 40,38 | 600 | 24.228 | Form 4 |
| ROIV | Epperly Melissa B, | Director | 15.09.2026 | Verkauf | 39,65 | 4.338 | 172.002 | Form 4 |
| ROIV | Fitzgerald Meghan | Director | 15.09.2026 | Verkauf | 40,45 | 400 | 16.180 | Form 4 |
| ROIV | Fitzgerald Meghan | Director | 15.09.2026 | Verkauf | 39,68 | 4.712 | 186.972 | Form 4 |
| ROIV | Epperly Melissa B, | Director | 10.09.2026 | Steuer-Abgabe | 40,94 | 2.179 | 89.208 | Form 4 |
| ROIV | Oren Ilan | Director | 10.09.2026 | Steuer-Abgabe | 40,94 | 2.378 | 97.355 | Form 4 |
| ROIV | Fitzgerald Meghan | Director | 10.09.2026 | Steuer-Abgabe | 40,94 | 1.743 | 71.358 | Form 4 |
| ROIV | Momtazee James C | Director | 10.09.2026 | Steuer-Abgabe | 40,94 | 2.905 | 118.931 | Form 4 |
| ROIV | Gold Daniel Allen | Director | 10.09.2026 | Steuer-Abgabe | 40,94 | 5.133 | 210.145 | Form 4 |
| ROIV | Fitzgerald Meghan | Director | 08.09.2026 | Verkauf | 39,90 | 20.000 | 798.000 | Form 4 |
| ROIV | Fitzgerald Meghan | Director | 08.09.2026 | Optionsausübung | 8,80 | 20.000 | 176.000 | Form 4 |
| ROIV | Venker Eric | President & Immunovant CEO | 28.08.2026 | Verkauf | 36,44 | 33.818 | 1.232.328 | Form 4 |
| ROIV | Venker Eric | President & Immunovant CEO | 28.08.2026 | Verkauf | 35,63 | 166.182 | 5.921.065 | Form 4 |
| ROIV | Venker Eric | President & Immunovant CEO | 28.08.2026 | Optionsausübung | 3,85 | 200.000 | 770.000 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 21.08.2026 | Verkauf | 36,48 | 144.756 | 5.280.699 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 21.08.2026 | Optionsausübung | 3,85 | 144.756 | 557.311 | Form 4 |
| ROIV | Pulik Richard | CFO | 20.08.2026 | Steuer-Abgabe | 36,84 | 5.749 | 211.793 | Form 4 |
| ROIV | Venker Eric | President & Immunovant CEO | 20.08.2026 | Steuer-Abgabe | 36,84 | 13.909 | 512.408 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 20.08.2026 | Verkauf | 37,30 | 17.519 | 653.459 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 20.08.2026 | Optionsausübung | 3,85 | 17.519 | 67.448 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 19.08.2026 | Verkauf | 37,17 | 172.899 | 6.426.656 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 19.08.2026 | Optionsausübung | 3,85 | 172.899 | 665.661 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 18.08.2026 | Verkauf | 37,18 | 31.801 | 1.182.361 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 18.08.2026 | Optionsausübung | 3,85 | 31.801 | 122.434 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 18.08.2026 | Verkauf | 36,59 | 105.141 | 3.847.109 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 18.08.2026 | Optionsausübung | 3,85 | 105.141 | 404.793 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 17.08.2026 | Verkauf | 36,25 | 284.707 | 10.320.629 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 17.08.2026 | Optionsausübung | 3,85 | 284.707 | 1.096.122 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 14.08.2026 | Verkauf | 36,23 | 243.177 | 8.810.303 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 14.08.2026 | Optionsausübung | 3,85 | 243.177 | 936.231 | Form 4 |
| ROIV | Venker Eric | President & Immunovant CEO | 27.07.2026 | Verkauf | 34,95 | 200.000 | 6.990.000 | Form 4 |
| ROIV | Venker Eric | President & Immunovant CEO | 27.07.2026 | Optionsausübung | 3,85 | 200.000 | 770.000 | Form 4 |
| ROIV | Momtazee James C | Director | 17.07.2026 | Zuteilung | — | 405 | — | Form 4 |
Kompakter Markt-Überblick — keine Anlageberatung. Quelle: Fundamentaldaten & SEC-Berichte (Geschäfts- und Quartalsberichte, 10-K/10-Q).